ClinicalTrials.gg
CompletedNCT01466348Updated Nov 25, 2013Results posted

Effects of a Common Cold Treatment on Cognitive Function

A Phase 4 interventional study of Paracetamol and Caffeine and Paracetamol in Common Cold, sponsored by GlaxoSmithKline. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-25.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies in Common Cold with a site in United Kingdom — none open to participants now, 1 under way, none of them phase 3. Common Cold · United Kingdom.

Enrollment
12th of 20
72 · median 89
Started
2011
with 2 others
Phase 4
5 of 20
none open now
Registered
7th of 20
by date
Lead sponsor
4 of 20
GlaxoSmithKline

Among the 20 studies in Common Cold with a site in United Kingdom, this one is the 12th largest by enrollment, is one of 3 that started in 2011, is one of 5 in phase 4, and was the 7th registered.

Common Cold

219 studies on the registry are indexed under Common Cold; 23 are open to participants now.

Browse Common Cold studies →

Open to participants now

None of the 20 studies in Common Cold with a site in United Kingdom is open now. The open studies under Common Cold, anywhere →

Who these studies take

Of the 14 Common Cold studies recruiting now, 4 (29%) set no upper age limit and 9 (64%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies in Common Cold with a site in United Kingdom as a file.
02

Study summary

A reduction in alertness and lower levels of performance are commonly associated with the common cold. Paracetamol has been shown to be more effective than placebo in treating symptoms associated with upper respiratory tract infection; caffeine has been shown to increase levels of alertness and improve performance of people suffering from colds. This study will investigate any improvement in alertness and performance based on cognitive function and mood assessment in subjects suffering from the common cold, when taking a novel paracetamol and caffeine combination verses paracetamol alone.

03

Conditions studied

  • Common Cold

Browse trials for

Keywords

  • Paracetomol
  • Caffeine
  • Common cold
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Present with symptoms of the common cold of no more than 96 hours duration
  • Score of "2" or more on a self-rating for malaise and at least 4 other cold symptoms

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation
  • to drugs
  • Have taken caffeine in the last 12 hours or treated their cold
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Paracetamol and Caffeine

    Paracetamol and caffeine

    Drug: Paracetamol and Caffeine

  • Active comparator
    Paracetamol

    Paracetamol

    Drug: Paracetamol

Interventions

06

What researchers measure

Primary outcomes

  1. Adjusted Mean Change From Baseline in Number of Valid Responses to Rapid Visual Information Processing (RVIP) Cognitive Test

    The RVIP assessed the performance of visual attention mechanisms in remaining vigilant to periodically occurring events. Participants monitored a series of single numbers (0-9) appearing in the centre of the screen. During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. The test lasted approximately 9 minutes and mean number of valid responses to stimulus was calculated.

    Time frame: Baseline to 30 minutes post treatment administration

Secondary outcomes

  1. Adjusted Mean Change From Baseline in Number of Valid Responses to RVIP Cognitive Test

    The RVIP assessed the performance of visual attention mechanisms in remaining vigilant to periodically occurring events. Participants monitored a series of single numbers (0-9) appearing in the centre of the screen. During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. The test lasted approximately 9 minutes and mean number of valid responses to stimulus was calculated.

    Time frame: Baseline to 60 minutes post treatment administration

  2. Adjusted Mean Change in Baseline in Valid Reaction Time to RVIP Cognitive Test

    The RVIP assessed the performance of visual attention mechanisms in remaining vigilant to periodically occurring events. Participants monitored a series of single numbers (0-9) appearing in the centre of the screen. During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. Mean valid reaction time was determined.

    Time frame: Baseline, 30 minutes and up to 60 minutes post treatment administration

  3. Mean Change From Baseline in Number of Incorrect and Missed Responses to RVIP Cognitive Test

    The RVIP assessed the performance of visual attention mechanisms in remaining vigilant to periodically occurring events. Participants monitored a series of single numbers (0-9) appearing in the centre of the screen. During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. The test lasted approximately 9 minutes and mean number of valid responses to stimulus was calculated.

    Time frame: Baseline, 30 minutes and up to 60 minutes post treatment administration

  4. Adjusted Mean Change From Baseline in Number of Valid Responses to Sustained Attention Tasks (SAT) Cognitive Test

    Auditory and visual attention of participants was evaluated using a validated Sustained Attention task. For the sustained visual attention task, participants were required to respond to the letter 's' every time it appears in a continuous stream of letters presented on a screen. For the sustained auditory attention task, participants responded to the number '8' every time it appears in a continuous stream of numbers presented through headphones. Total test duration was approximately 6 minutes. Mean values of valid responses to visual and auditory tests were calculated.

    Time frame: Baseline, 30 minutes and up to 60 minutes post treatment administration

  5. Mean Change From Baseline in Number of Incorrect and Missed Responses to SAT Cognitive Test

    Auditory and visual attention of participants was evaluated using a validated Sustained Attention task. For the sustained visual attention task, participants were required to respond to the letter 's' every time it appears in a continuous stream of letters presented on a screen. For the sustained auditory attention task, participants responded to the number '8' every time it appears in a continuous stream of numbers presented through headphones. Total test duration was approximately 6 minutes. Mean values of incorrect and missed responses to visual and auditory tests were calculated.

    Time frame: Baseline, 30 minutes and up to 60 minutes post treatment administration

  6. Adjusted Mean Change From Baseline in Valid Reaction Time to SAT Cognitive Test

    Auditory and visual attention of participants was evaluated using a validated Sustained Attention task. For the sustained visual attention task, participants were required to respond to the letter 's' every time it appears in a continuous stream of letters presented on a screen. For the sustained auditory attention task, participants responded to the number '8' every time it appears in a continuous stream of numbers presented through headphones. Total test duration was approximately 6 minutes. Mean values of valid reaction time to visual and auditory tests were calculated.

    Time frame: Baseline, 30 minutes and up to 60 minutes post treatment administration

  7. Adjusted Mean Change From Baseline in Number of Valid Responses to Divided Attention Task (DAT) Cognitive Test

    For the DAT Cognitive test, auditory and visual stimuli were simultaneously presented and participants were asked to respond to occurrences of 's' (visual) or '8' (auditory). Total test duration was approximately 6 minutes. Mean values of valid responses to visual and auditory tests were calculated.

    Time frame: Baseline, 30 minutes and up to 60 minutes post treatment administration

  8. Adjusted Mean Change From Baseline in Valid Reaction Time to DAT Cognitive Test

    For the DAT Cognitive test, auditory and visual stimuli were simultaneously presented and participants were asked to respond to occurrences of 's' (visual) or '8' (auditory). Total test duration was approximately 6 minutes. Mean values of valid reaction time to visual and auditory tests were calculated.

    Time frame: Baseline, 30 minutes and up to 60 minutes post treatment administration

  9. Mean Change From Baseline in Number of Incorrect and Missed Responses to DAT Cognitive Test

    For the DAT Cognitive test, auditory and visual stimuli were simultaneously presented and participants were asked to respond to occurrences of 's' (visual) or '8' (auditory). Total test duration was approximately 6 minutes. Mean values of incorrect and missed responses to visual and auditory tests were calculated.

    Time frame: Baseline, 30 minutes and up to 60 minutes post treatment administration

  10. Adjusted Mean Change From Baseline in Mood Alertness and Physical Sensation Scales (MAPSS) Cognitive Test

    Mood patterns was evaluated using the Mood, Alertness and Physical Sensation Scales (MAPSS) which comprised of 23 questions describing moods and physical sensations, on a 9-point scale anchored at the left hand end with 'not at all' and the right hand end with 'extremely'. For each question, '9' represented the 'best' score and '1' represented the 'worst' score. Mean score was calculated by summing the responses and dividing by the number of questions answered. MAPSS Questionnaire was further divided into three main clusters: Alertness; Anxiety and Headache as per the questions.

    Time frame: Baseline, 30 minutes and up to 60 minutes post treatment administration

07

Results

Posted Nov 25, 2013
Limitations and caveats
Apparent carryover effect from the paracetamol/ caffeine treatment taken in Period 1 into the baseline assessment of Period 2 was observed, hence the statistical analysis was amended after unblinding the statistician.

Participant flow

Participants were recruited at the clinical site.

Period I - First Intervention
Participant flow — Period I - First Intervention
MilestoneParacetamol/ Caffeine Tablet Then Paracetamol PowderParacetamol Powder Then Paracetamol/ Caffeine Tablet
Started3636
Intent to treat (itt) population3635
Completed3635
Not completed01
Withdrew: Withdrawal by subject01
Period II - Second Intervention
Participant flow — Period II - Second Intervention
MilestoneParacetamol/ Caffeine Tablet Then Paracetamol PowderParacetamol Powder Then Paracetamol/ Caffeine Tablet
Started3536
Completed3536
Not completed00

Outcome measures

PrimaryAdjusted Mean Change From Baseline in Number of Valid Responses to Rapid Visual Information Processing (RVIP) Cognitive Test

The RVIP assessed the performance of visual attention mechanisms in remaining vigilant to periodically occurring events. Participants monitored a series of single numbers (0-9) appearing in the centre of the screen. During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. The test lasted approximately 9 minutes and mean number of valid responses to stimulus was calculated.

Time frame:
Baseline to 30 minutes post treatment administration
Reported as:
Mean · Valid responses
Adjusted Mean Change From Baseline in Number of Valid Responses to Rapid Visual Information Processing (RVIP) Cognitive Test
Valid responsesParacetamol/ Caffeine TabletParacetamol Powder
Adjusted Mean Change From Baseline in Number of Valid Responses to Rapid Visual Information Processing (RVIP) Cognitive Test4.8 ± 0.801.3 ± 0.80
Statistical analysis
  • Paracetamol/ Caffeine Tablet vs Paracetamol Powder · ANOVA · p = 0.0008 · Adjusted mean difference: 3.6 · 95% CI 1.5 to 5.6A positive difference favors the paracetamol/ caffeine treatment.
SecondaryAdjusted Mean Change From Baseline in Number of Valid Responses to RVIP Cognitive Test

The RVIP assessed the performance of visual attention mechanisms in remaining vigilant to periodically occurring events. Participants monitored a series of single numbers (0-9) appearing in the centre of the screen. During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. The test lasted approximately 9 minutes and mean number of valid responses to stimulus was calculated.

Time frame:
Baseline to 60 minutes post treatment administration
Reported as:
Mean · Valid responses
Adjusted Mean Change From Baseline in Number of Valid Responses to RVIP Cognitive Test
Valid responsesParacetamol/ Caffeine TabletParacetamol Powder
Adjusted Mean Change From Baseline in Number of Valid Responses to RVIP Cognitive Test7.1 ± 0.930.6 ± 0.93
Statistical analysis
  • Paracetamol/ Caffeine Tablet vs Paracetamol Powder · ANOVA · p = <0.0001 · Adjusted mean difference: 6.5 · 95% CI 4.5 to 8.4A positive difference favors the paracetamol/ caffeine treatment.
SecondaryAdjusted Mean Change in Baseline in Valid Reaction Time to RVIP Cognitive Test

The RVIP assessed the performance of visual attention mechanisms in remaining vigilant to periodically occurring events. Participants monitored a series of single numbers (0-9) appearing in the centre of the screen. During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. Mean valid reaction time was determined.

Time frame:
Baseline, 30 minutes and up to 60 minutes post treatment administration
Reported as:
Mean · milliseconds (msec)
Adjusted Mean Change in Baseline in Valid Reaction Time to RVIP Cognitive Test
milliseconds (msec)Paracetamol/ Caffeine TabletParacetamol Powder
30 minutes6.00 ± 3.9161.88 ± 3.916
60 minutes0.08 ± 3.983-4.85 ± 3.954
SecondaryMean Change From Baseline in Number of Incorrect and Missed Responses to RVIP Cognitive Test

The RVIP assessed the performance of visual attention mechanisms in remaining vigilant to periodically occurring events. Participants monitored a series of single numbers (0-9) appearing in the centre of the screen. During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. The test lasted approximately 9 minutes and mean number of valid responses to stimulus was calculated.

Time frame:
Baseline, 30 minutes and up to 60 minutes post treatment administration
Reported as:
Mean · Responses
Mean Change From Baseline in Number of Incorrect and Missed Responses to RVIP Cognitive Test
ResponsesParacetamol/ Caffeine TabletParacetamol Powder
Incorrect responses at 30 minutes-2.3 ± 1.57-2.7 ± 1.52
Incorrect responses at 60 minutes-1.7 ± 1.93-2.7 ± 1.80
Missed responses at 30 minutes-4.8 ± 0.69-1.3 ± 0.89
Missed responses at 60 minutes-7.1 ± 0.90-0.6 ± 1.00
SecondaryAdjusted Mean Change From Baseline in Number of Valid Responses to Sustained Attention Tasks (SAT) Cognitive Test

Auditory and visual attention of participants was evaluated using a validated Sustained Attention task. For the sustained visual attention task, participants were required to respond to the letter 's' every time it appears in a continuous stream of letters presented on a screen. For the sustained auditory attention task, participants responded to the number '8' every time it appears in a continuous stream of numbers presented through headphones. Total test duration was approximately 6 minutes. Mean values of valid responses to visual and auditory tests were calculated.

Time frame:
Baseline, 30 minutes and up to 60 minutes post treatment administration
Reported as:
Mean · Valid responses
Adjusted Mean Change From Baseline in Number of Valid Responses to Sustained Attention Tasks (SAT) Cognitive Test
Valid responsesParacetamol/ Caffeine TabletParacetamol Powder
30 minutes1.8 ± 0.52-0.5 ± 0.51
60 minutes1.5 ± 0.55-0.7 ± 0.55
SecondaryMean Change From Baseline in Number of Incorrect and Missed Responses to SAT Cognitive Test

Auditory and visual attention of participants was evaluated using a validated Sustained Attention task. For the sustained visual attention task, participants were required to respond to the letter 's' every time it appears in a continuous stream of letters presented on a screen. For the sustained auditory attention task, participants responded to the number '8' every time it appears in a continuous stream of numbers presented through headphones. Total test duration was approximately 6 minutes. Mean values of incorrect and missed responses to visual and auditory tests were calculated.

Time frame:
Baseline, 30 minutes and up to 60 minutes post treatment administration
Reported as:
Mean · Responses
Mean Change From Baseline in Number of Incorrect and Missed Responses to SAT Cognitive Test
ResponsesParacetamol/Caffeine TabletParacetamol Powder
Incorrect responses at 30 minutes-2.3 ± 0.630.1 ± 0.65
Incorrect responses at 60 minutes-3.6 ± 0.710.6 ± 0.72
Missed responses at 30 minutes-1.8 ± 0.590.5 ± 0.44
Missed responses at 60 minutes-1.5 ± 0.540.7 ± 0.55
SecondaryAdjusted Mean Change From Baseline in Valid Reaction Time to SAT Cognitive Test

Auditory and visual attention of participants was evaluated using a validated Sustained Attention task. For the sustained visual attention task, participants were required to respond to the letter 's' every time it appears in a continuous stream of letters presented on a screen. For the sustained auditory attention task, participants responded to the number '8' every time it appears in a continuous stream of numbers presented through headphones. Total test duration was approximately 6 minutes. Mean values of valid reaction time to visual and auditory tests were calculated.

Time frame:
Baseline, 30 minutes and up to 60 minutes post treatment administration
Reported as:
Mean · msec
Adjusted Mean Change From Baseline in Valid Reaction Time to SAT Cognitive Test
msecParacetamol/ Caffeine TabletParacetamol Powder
30 minutes-6.49 ± 2.80-6.18 ± 2.75
60 minutes-10.69 ± 3.12-9.45 ± 3.10
SecondaryAdjusted Mean Change From Baseline in Number of Valid Responses to Divided Attention Task (DAT) Cognitive Test

For the DAT Cognitive test, auditory and visual stimuli were simultaneously presented and participants were asked to respond to occurrences of 's' (visual) or '8' (auditory). Total test duration was approximately 6 minutes. Mean values of valid responses to visual and auditory tests were calculated.

Time frame:
Baseline, 30 minutes and up to 60 minutes post treatment administration
Reported as:
Mean · Valid responses
Adjusted Mean Change From Baseline in Number of Valid Responses to Divided Attention Task (DAT) Cognitive Test
Valid responsesParacetamol/ Caffeine TabletParacetamol Powder
30 minutes6.8 ± 1.002.0 ± 0.99
60 minutes7.4 ± 1.011.9 ± 1.00
SecondaryAdjusted Mean Change From Baseline in Valid Reaction Time to DAT Cognitive Test

For the DAT Cognitive test, auditory and visual stimuli were simultaneously presented and participants were asked to respond to occurrences of 's' (visual) or '8' (auditory). Total test duration was approximately 6 minutes. Mean values of valid reaction time to visual and auditory tests were calculated.

Time frame:
Baseline, 30 minutes and up to 60 minutes post treatment administration
Reported as:
Mean · msec
Adjusted Mean Change From Baseline in Valid Reaction Time to DAT Cognitive Test
msecParacetamol/ Caffeine TabletParacetamol Powder
30 Minutes1.65 ± 2.10-7.42 ± 2.07
60 minutes-5.49 ± 2.44-12.39 ± 2.43
SecondaryMean Change From Baseline in Number of Incorrect and Missed Responses to DAT Cognitive Test

For the DAT Cognitive test, auditory and visual stimuli were simultaneously presented and participants were asked to respond to occurrences of 's' (visual) or '8' (auditory). Total test duration was approximately 6 minutes. Mean values of incorrect and missed responses to visual and auditory tests were calculated.

Time frame:
Baseline, 30 minutes and up to 60 minutes post treatment administration
Reported as:
Mean · Responses
Mean Change From Baseline in Number of Incorrect and Missed Responses to DAT Cognitive Test
ResponsesParacetamol/Caffeine TabletParacetamol Powder
Incorrect responses at 30 minutes-5.4 ± 0.83-1.4 ± 0.83
Incorrect responses at 60 minutes-5.2 ± 0.77-0.2 ± 0.92
Missed responses at 30 minutes-6.7 ± 1.19-2.0 ± 0.83
Missed responses at 60 minutes-7.4 ± 1.24-1.9 ± 0.75
SecondaryAdjusted Mean Change From Baseline in Mood Alertness and Physical Sensation Scales (MAPSS) Cognitive Test

Mood patterns was evaluated using the Mood, Alertness and Physical Sensation Scales (MAPSS) which comprised of 23 questions describing moods and physical sensations, on a 9-point scale anchored at the left hand end with 'not at all' and the right hand end with 'extremely'. For each question, '9' represented the 'best' score and '1' represented the 'worst' score. Mean score was calculated by summing the responses and dividing by the number of questions answered. MAPSS Questionnaire was further divided into three main clusters: Alertness; Anxiety and Headache as per the questions.

Time frame:
Baseline, 30 minutes and up to 60 minutes post treatment administration
Reported as:
Mean · Score on a scale
Adjusted Mean Change From Baseline in Mood Alertness and Physical Sensation Scales (MAPSS) Cognitive Test
Score on a scaleParacetamol/Caffeine TabletParacetamol Powder
Alertness at 30 minutes0.8 ± 0.120.2 ± 0.12
Alertness at 60 minutes0.7 ± 0.130.1 ± 0.13
Anxiety at 30 minutes0.2 ± 0.080.2 ± 0.08
Anxiety at 60 minutes0.3 ± 0.080.4 ± 0.08
Headache at 30 minutes0.4 ± 0.100.4 ± 0.10
Headache at 60 minutes0.6 ± 0.100.6 ± 0.10

Adverse events

Collected over Adverse Events were collected from the start of the investigational product and until 5 days following last administration of the investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paracetamol/Caffeine Tablet—0/71 (0%)0/71 (0%)
Paracetamol Powder—0/71 (0%)0/71 (0%)

Baseline characteristics

Age Continuous
Age Continuous(Years)All Randomized Participants
Mean20.8 ± 4.19
Sex: Female, Male
Sex: Female, Male(Participants)All Randomized Participants
Female47
Male24
08

Study locations

1 site
  • Common Cold Centre
    Cardiff, Wales, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2011
First posted
Nov 6, 2011
Start
Feb 2011
Primary completionActual
Apr 2011
CompletionActual
Apr 2011
Results first posted
Nov 25, 2013
Last update
Nov 25, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01466348
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 6, 2011
Start date
Feb 2011
Primary completion
Apr 2011
Completion
Apr 2011
Results posted
Nov 25, 2013
Last update
Nov 25, 2013

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acetaminophen · Caffeine

Start the discussion